Cargando…

Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method

BACKGROUND: HER2/Neu (ErbB-2) overexpression, which occurs in 15–20% of breast cancer cases, is associated with better response to treatment with the drug trastuzumab. PhosphoHER2 (pHER2) has been evaluated for prediction of response to trastuzumab. Both markers are heterogeneously detected and are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yalai, Cheng, Huan, Bordeaux, Jennifer, Neumeister, Veronique, Kumar, Sudha, Rimm, David L., Stern, David F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836903/ https://www.ncbi.nlm.nih.gov/pubmed/24278211 http://dx.doi.org/10.1371/journal.pone.0079901

Ejemplares similares

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
por: Ahn, Sangjeong, et al.
Publicado: (2015)

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens
por: Tsuda, Hitoshi, et al.
Publicado: (2010)

Her2 Status Discrepancy Between Core Needle Biopsy and Surgically Resected Mastectomy Specimen: A Clinical Case
por: Vasques, Ana Carolina, et al.
Publicado: (2023)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens
por: Feng, Wenqin, et al.
Publicado: (2023)

Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer
por: Xu, Chen, et al.
Publicado: (2017)

Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis
por: Zhou, Jian, et al.
Publicado: (2019)

Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China
por: Xu, Chen, et al.
Publicado: (2022)

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark(®)) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens
por: Larson, Jeffrey S., et al.
Publicado: (2010)

Employing multiplex immunofluorescence to quantify Her2 and phosphorylated Her2 in formalin-fixed, paraffin-embedded breast tumor specimens
por: Donovan, MJ, et al.
Publicado: (2009)

Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies
por: Zhang, Qingyu, et al.
Publicado: (2016)

Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
por: Farahmand, Saman, et al.
Publicado: (2022)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies
por: Becker, Ricardo Gehrke, et al.
Publicado: (2013)

Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer
por: Tominaga, Naoyuki, et al.
Publicado: (2015)

High Concordance of a Closed-System, RT-qPCR Breast Cancer Assay for HER2 mRNA, Compared to Clinically Determined Immunohistochemistry, Fluorescence in situ Hybridization, and Quantitative Immunofluorescence
por: Wasserman, Brad E., et al.
Publicado: (2017)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Image Analysis of HER2 Immunohistochemical Staining of Surgical Breast Cancer Specimens
por: Yim, Kwangil, et al.
Publicado: (2019)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
por: Tang, Daoqiang, et al.
Publicado: (2014)

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma
por: Daveau, C, et al.
Publicado: (2014)

Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
por: Huai, Jianguo, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
por: YUAN, KAI, et al.
Publicado: (2015)

Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer
por: Qiu, Miao-Zhen, et al.
Publicado: (2017)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m5k09f4uli59r810oecloudlon